Glenmark Pharmaceuticals Europe competitive analysis

Latest publications and patents of Glenmark Pharmaceuticals Europe New

Explore the latest publications and patents granted to Glenmark Pharmaceuticals Europe, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Glenmark Pharmaceuticals Europe against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Rapid Dissolution Formulation Of A Calcium Receptor-Active CompoundAMGENAug 30, 2023
Compositions And Uses For Treating Multiple SclerosisBIOGEN IDEC MAApr 19, 2023
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISOct 12, 2022
Oral Pharmaceutical Compositions Of Dabigatran EtexilateESTEVE PHARMACEUTICALSApr 14, 2022
Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGYJan 14, 2022
Novel Antitumoral Use Of CabazitaxelAVENTIS PHARMAMar 10, 2021
Rapid Dissolution Formulation Of Cinacalcet HclAMGENJan 27, 2020
Rapid Dissolution Formulation Of A Calcium Receptor-Active CompoundAMGENJan 16, 2020
Rapid Dissolution Formulation Of A Cinacalcet HclAMGENJan 16, 2020
Rapid Dissolution Formulation Of Cinacalcet HclAMGENJan 16, 2020

Latest PTAB cases involving Glenmark Pharmaceuticals Europe

Discover the latest PTAB cases involving Glenmark Pharmaceuticals Europe, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Glenmark Pharmaceuticals Europe with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
GLENMARK PHARMACEUTICALS EUROPE12 - - - Highly Aggressive
AMGEN8132811Defensive
EURO CELTIQUE - 44 - - Non-Active
MUNDIPHARMA - 25 - - Non-Active